Literature DB >> 8282322

Combination treatment of enalapril with nitrendipine in rats with renovascular hypertension.

U O Wenzel1, U Helmchen, W Schoeppe, G Schwietzer.   

Abstract

We have recently shown that treatment with the calcium channel blocker nitrendipine may aggravate albuminuria and glomerular injury in rats with two-kidney, one clip renovascular hypertension if arterial blood pressure is not reduced. To test whether nitrendipine also exerts its adverse renal effects when normotension is achieved, we examined the effect of combined therapy with nitrendipine and the converting enzyme inhibitor enalapril on blood pressure, albuminuria, glomerular filtration rate, and morphology of the nonclipped kidney. Rats treated with enalapril alone or in combination with the diuretic hydrochlorothiazide or rats treated with nitrendipine alone served as controls. Therapy was started 6 weeks after clipping of one renal artery. Nitrendipine alone did not reduce blood pressure but significantly increased albuminuria, diuresis, glomerular filtration rate, and glomerular volume and injury compared with untreated hypertensive controls. Increase of glomerular filtration rate, diuresis, and albuminuria was reversible after withdrawal of nitrendipine. Treatment with enalapril alone decreased blood pressure significantly but not to normotensive levels and was without significant effect on albuminuria and glomerular morphology. The combination of nitrendipine and enalapril reduced blood pressure to normotensive levels and not only prevented the increase of glomerular volume, glomerular filtration rate, diuresis, and albuminuria caused by nitrendipine alone but furthermore improved glomerular injury and albuminuria to levels not significantly different from normotensive controls. Enalapril in combination with the diuretic had similar beneficial effects on blood pressure, albuminuria, and glomerular injury. These data demonstrate that the adverse effects of nitrendipine monotherapy on glomerular structure and function can be prevented by the combination of nitrendipine and enalapril when blood pressure is normalized.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8282322     DOI: 10.1161/01.hyp.23.1.114

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  4 in total

Review 1.  Calcium antagonists. Drug interactions of clinical significance.

Authors:  T Rosenthal; D Ezra
Journal:  Drug Saf       Date:  1995-09       Impact factor: 5.606

2.  The case for combining angiotensin-converting enzyme inhibitors and calcium-channel blockers.

Authors:  A A Taylor; S Sunthornyothin
Journal:  Curr Hypertens Rep       Date:  1999-10       Impact factor: 5.369

3.  Calcium-channel blockers and the progression of renal disease.

Authors:  K A Griffin; A K Bidani
Journal:  Curr Hypertens Rep       Date:  1999-10       Impact factor: 5.369

4.  [Theoretical model of a cost-effectiveness analysis of combined enalapril-nitrendipine therapy for treating hypertension].

Authors:  F Antoñanzas; M Velasco; I Abbas; C Pontes; J Delgadillo; M Terán
Journal:  Aten Primaria       Date:  2003       Impact factor: 1.137

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.